-
Product Insights
New![]()
Net Present Value Model: Atara Biotherapeutics Inc’s ATA-188
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Atara Biotherapeutics Inc’s ATA-2271
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATA-2271 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ATA-2271 in Solid Tumor Drug Details:ATA-2271 is under development for the treatment of solid tumors and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATA-190 in Nasopharyngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ATA-190 in Nasopharyngeal CancerDrug Details:ATA-190Â is under development for the treatment of metastatic EBV-associated nasopharyngeal carcinoma....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATA-2271 in Malignant Pleural Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ATA-2271 in Malignant Pleural Mesothelioma Drug Details:ATA-2271 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evruleucel in Primary Progressive Multiple Sclerosis (PPMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Evruleucel in Primary Progressive Multiple Sclerosis (PPMS) Drug Details: Evruleucel (ATA-188) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evruleucel in Secondary Progressive Multiple Sclerosis (SPMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Evruleucel in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details: Evruleucel (ATA-188) is under development for...
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s RG-6341
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CBP-1019 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1019 in Solid Tumor Drug Details: CBP-1019 is under development for the treatment of lung...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HST-1011 in Rectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HST-1011 in Rectal CancerDrug Details: HST-1011 is under development for solid tumors including ovarian cancer, anal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.